التفاصيل البيبلوغرافية
| العنوان: |
Overcoming therapeutic challenges: Successful management of a supposedly triple seronegative, refractory generalized myasthenia gravis patient with efgartigimod. |
| المؤلفون: |
Sorrenti, Benedetta, Laurini, Christian, Bosco, Luca, Strano, Camilla Mirella Maria, Scarlato, Marina, Gastaldi, Matteo, Filippi, Massimo, Previtali, Stefano Carlo, Falzone, Yuri Matteo |
| المصدر: |
European Journal of Neurology; Jul2024, Vol. 31 Issue 7, p1-5, 5p |
| مصطلحات موضوعية: |
MYASTHENIA gravis, FC receptors, CHOLINERGIC receptors, REFRACTORY materials, THERAPEUTICS, TREATMENT effectiveness |
| مصطلحات جغرافية: |
AMERICA |
| الشركة/الكيان: |
EUROPEAN Medicines Agency, UNITED States. Food & Drug Administration |
| مستخلص: |
Background and purpose: This study was undertaken to highlight neonatal Fc receptor inhibition (efgartigimod) as a valuable therapeutic option for patients with refractory seronegative myasthenia gravis (MG) and to emphasize the concept that seronegative MG is greatly constrained by the limitations of currently available diagnostic methods and therapeutic measures. Methods: We describe the first refractory, generalized MG (gMG) patient successfully treated with efgartigimod after testing negative on standard autoantibody detection tests. Results: Our patient presented with severe fluctuating bulbar and generalized weakness, resulting in multiple myasthenic crises requiring intubation. After a 28‐year medical history of multiple failed lines of treatment, our patient was started on efgartigimod. Over five treatment cycles, a definite improvement in her clinical condition was observed (Myasthenia Gravis Foundation of America class: IIIb to IIb; MG‐Activities of Daily Living score: 11 to 0; MG‐Quality of Life 15 score: 30 to 0; Quantitative MG score: 28 to 6). Standard autoantibody detection tests failed to detect known pathogenic autoantibodies, but cell‐based assay (CBA) identified autoantibodies against clustered adult acetylcholine receptor (AChR). Conclusions: In light of recent approvals of efgartigimod by the European Medicines Agency and US Food and Drug Administration exclusively for AChR‐positive gMG forms, our case highlights evidence suggesting that such an approach might be shortsighted and could limit therapeutic options for patients with refractory seronegative gMG. Additionally, introducing more sensitive analytical techniques, exemplified by CBA, may help bridge the gap between seronegative and seropositive patients. This represents an urgent unmet need for gMG patients, as the antibody profile dramatically influences the therapeutic approach. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder